Challenges of Anti-Mesothelin CAR-T-Cell Therapy

Challenges of Anti-Mesothelin CAR-T-Cell Therapy

Chimeric antigen receptor (CAR)-T-cell therapy is a kind of adoptive T-cell therapy (ACT) that has developed rapidly in recent years. Mesothelin (MSLN) is a tumor-associated antigen (TAA) that is highly expressed in various solid tumors and is an important target antigen for the development of new i...

Full description

Bibliographic Details
Main Authors: Xuejia Zhai, Ling Mao, Min Wu, Jie Liu, Shicang Yu
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Cancers
Subjects:
chimeric antigen receptor T cells (CAR-T cells)
mesothelin
clinical trial
solid tumor
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/15/5/1357

Similar Items

Similar Items